Founded in San Diego, California, HUYA Bioscience International LLC focuses on advancing pharmaceutical research and the global marketing of early-stage compounds. The company's core mission is to meet unmet medical needs by accelerating the global development of novel biopharmaceutical products originating in China. HUYA leverages strategic partnerships to position promising compounds for development in international markets, offering a unique advantage through its world-class commercial scientific expertise.
Notable figures affiliated with HUYA include President & CEO Dr. Mireille Gillings. The company has achieved significant milestones in globalizing China's biopharma innovation, enabling faster, more cost-effective, and lower-risk drug development. HUYA's impact is evident in its ability to bridge the gap between Chinese biopharma innovations and global markets, thereby enhancing the availability of cutting-edge medical treatments worldwide.
Quick Facts
When was Huya Bioscience International's last funding round?
Huya Bioscience International's most recent funding round was for $48M (USD) in April 2015.
How much disclosed funding has Huya Bioscience International raised?
As of Apr 22, 2015, Huya Bioscience International has disclosed funding of $60.6M (USD).